MCID: SML011
MIFTS: 33

Smoldering Myeloma

Categories: Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Smoldering Myeloma

MalaCards integrated aliases for Smoldering Myeloma:

Name: Smoldering Myeloma 12 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:9551
UMLS 73 C1531608

Summaries for Smoldering Myeloma

Disease Ontology : 12 A multiple myeloma that is a slow growing type of myeloma in which abnormal plasma cells results in too much of a single type of monoclonal antibody.

MalaCards based summary : Smoldering Myeloma is related to monoclonal gammopathy of uncertain significance and myeloma, multiple, and has symptoms including bone pain An important gene associated with Smoldering Myeloma is MYOM2 (Myomesin 2), and among its related pathways/superpathways are Keratan sulfate/keratin metabolism and N-Glycan biosynthesis. The drugs Lenalidomide and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and b cells.

Related Diseases for Smoldering Myeloma

Graphical network of the top 20 diseases related to Smoldering Myeloma:



Diseases related to Smoldering Myeloma

Symptoms & Phenotypes for Smoldering Myeloma

UMLS symptoms related to Smoldering Myeloma:


bone pain

Drugs & Therapeutics for Smoldering Myeloma

Drugs for Smoldering Myeloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 107)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenalidomide Approved Phase 3,Phase 2,Phase 1 191732-72-6 216326
2
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
3
Daratumumab Approved Phase 3,Phase 2 945721-28-8
4
Mechlorethamine Approved, Investigational Phase 3,Phase 1,Phase 2 51-75-2 4033
5
Melphalan Approved Phase 3,Phase 2,Phase 1 148-82-3 4053 460612
6 Dexamethasone acetate Phase 3,Phase 2,Phase 1 1177-87-3
7 Alkylating Agents Phase 3,Phase 2,Phase 1
8 glucocorticoids Phase 3,Phase 2,Phase 1
9
protease inhibitors Phase 3,Phase 2,Phase 1
10 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
11 HIV Protease Inhibitors Phase 3,Phase 2,Phase 1
12 Hormone Antagonists Phase 3,Phase 2,Phase 1
13 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
14 Hormones Phase 3,Phase 2,Phase 1
15 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
17 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
18 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
19 Antibodies Phase 3,Phase 2,Phase 1
20 Immunoglobulins Phase 3,Phase 2,Phase 1
21 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
22 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
23 Anti-Infective Agents Phase 3,Phase 2,Phase 1
24 Antiemetics Phase 3,Phase 2,Phase 1
25 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1
26 BB 1101 Phase 3,Phase 2,Phase 1
27 Autonomic Agents Phase 3,Phase 2,Phase 1
28 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
29 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
30 Nitrogen Mustard Compounds Phase 3
31 phenylalanine Nutraceutical Phase 3,Phase 1,Phase 2
32 alanine Nutraceutical Phase 3
33
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
34
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
35 sodium fluoride Approved Phase 2 7681-49-4
36
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
37 Siltuximab Approved, Investigational Phase 2,Phase 1 541502-14-1
38
Ranitidine Approved Phase 2 66357-59-3, 66357-35-5 3001055
39
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
40
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
41
Histamine Approved, Investigational Phase 2 75614-87-8, 51-45-6 774
42
Promethazine Approved, Investigational Phase 2 60-87-7 4927
43
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
44 Ixazomib Approved, Investigational Phase 2,Phase 1 1072833-77-2
45
Lenograstim Approved, Investigational Phase 1, Phase 2 135968-09-1
46
nivolumab Approved Phase 2 946414-94-4
47
Bortezomib Approved, Investigational Phase 2,Phase 1 179324-69-7 387447 93860
48
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
49
Glycine Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 56-40-6 750
50
Epigallocatechin gallate Investigational Phase 2 989-51-5 65064

Interventional clinical trials:

(show top 50) (show all 57)
# Name Status NCT ID Phase Drugs
1 QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression Completed NCT00480363 Phase 3
2 Thalidomide for Multiple Myeloma Completed NCT00038233 Phase 3 Thalidomide
3 A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma Recruiting NCT03301220 Phase 3 Daratumumab SC: daratumumab + rHuPH20
4 Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Active, not recruiting NCT01169337 Phase 3 Lenalidomide
5 Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant Active, not recruiting NCT00114101 Phase 3 Lenalidomide;Melphalan
6 Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma Completed NCT01441973 Phase 2
7 Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma Completed NCT01222286 Phase 2 IPH2101
8 Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma Completed NCT01302886 Phase 2 BHQ880
9 Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma Completed NCT00099047 Phase 2 celecoxib;placebo
10 UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma Completed NCT01884688 Phase 2 ENK Cell Infusion
11 Imaging in MGUS, SMM and MM Completed NCT01237054 Phase 2 18-NaF PET;18-FDG PET/CT
12 Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy Completed NCT01094548 Phase 2 Single low dose cyclophosphamide;Multiple low dose cyclophosphamide
13 Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma Completed NCT00635154 Phase 2 Dexamethasone acetate
14 Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients Recruiting NCT02943473 Phase 2 Ibrutinib
15 Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma Recruiting NCT02916771 Phase 2 Ixazomib;Lenalidomide;Dexamethasone
16 Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma Recruiting NCT03236428 Phase 2 Daratumumab
17 Trial of Isatuximab (SAR650984) in Patients With High Risk Smoldering Multiple Myeloma Recruiting NCT02960555 Phase 2 Isatuximab;Diphenhydramine;Ranitidine;Methylprednisolone
18 Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma Recruiting NCT01572480 Phase 2 Carfilzomib;Revlimid;Dexamethasone
19 Trial of Combination of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma Active, not recruiting NCT02279394 Phase 2 Elotuzumab;Lenalidomide;Dexamethasone
20 A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma Active, not recruiting NCT01484275 Phase 2 Siltuximab;Placebo
21 Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma Active, not recruiting NCT02415413 Phase 2 carfilzomib;Lenalidomide;Dexamethasone;Melphalan
22 A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma Active, not recruiting NCT02316106 Phase 2 daratumumab;daratumumab;daratumumab
23 Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma Active, not recruiting NCT00112827 Phase 1, Phase 2 melphalan;cyclophosphamide;lenalidomide
24 Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant Not yet recruiting NCT03289299 Phase 2 Carfilzomib;Lenalidomide;Daratumumab;Dexamethasone
25 A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma Suspended NCT02903381 Phase 2 Nivolumab;Lenalidomide;Dexamethasone
26 Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma Suspended NCT02492750 Phase 1, Phase 2 Dexamethasone;Lenalidomide
27 Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients Terminated NCT00983346 Phase 2 Bortezomib
28 A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma Terminated NCT01248455 Phase 2 (Anti-KIR)
29 A Phase II Study of BI-505 in Smoldering Multiple Myeloma Terminated NCT01838369 Phase 2 BI-505
30 A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma Terminated NCT01302366 Phase 2 TBL12
31 Study of TBL 12 Sea Cucumber Extract for Patients With Untreated Asymptomatic Myeloma Terminated NCT01096810 Phase 2 TBL 12
32 Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma Terminated NCT00942422 Phase 2
33 Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM) Terminated NCT00899353 Phase 2
34 Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma Terminated NCT02353572 Phase 1, Phase 2 Melphalan;Bortezomib;Dexamethasone
35 Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma Withdrawn NCT00503763 Phase 2 Simvastatin
36 MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma Withdrawn NCT01660997 Phase 2 MLN9708;Dexamethasone
37 Imaging Studies and the Development of Multiple Myeloma Withdrawn NCT01571726 Phase 2 Fluciclatide
38 Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer Unknown status NCT02240537 Phase 1 Sargramostim;BB-MPI-03;Montanide
39 Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma Completed NCT01718899 Phase 1
40 A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma Completed NCT01219010 Phase 1
41 Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma Completed NCT00698776 Phase 1 Lenalidomide
42 Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study Active, not recruiting NCT02697383 Phase 1 Ixazomib (MLN9708);Dexamethasone
43 A Study of PVX-410, a Cancer Vaccine, and Durvalumab +/- Lenalidomide for Smoldering MM Active, not recruiting NCT02886065 Phase 1 Hiltonol;Durvalumab;Lenalidomide
44 Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma Suspended NCT02784483 Phase 1 Atezolizumab (1200mg via IV infusion)
45 Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM) Completed NCT01109407
46 Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma Completed NCT01955395 Not Applicable
47 S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS. Completed NCT00919139
48 Prospective Observational Study of Clinical and Genomic Predictors of Progression to Myeloma in Asymptomatic Monoclonal Gammopathies Recruiting NCT02726750
49 Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome Recruiting NCT02269592
50 A Diagnostic Screening Trial Seeking AL Amyloidosis Very Early Recruiting NCT02741999

Search NIH Clinical Center for Smoldering Myeloma

Genetic Tests for Smoldering Myeloma

Anatomical Context for Smoldering Myeloma

MalaCards organs/tissues related to Smoldering Myeloma:

41
Bone, Bone Marrow, B Cells, Heart, T Cells

Publications for Smoldering Myeloma

Articles related to Smoldering Myeloma:

(show all 38)
# Title Authors Year
1
Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients. ( 29907380 )
2018
2
The pattern of the M-protein in smoldering myeloma over the time: an evolving risk factor. ( 29795240 )
2018
3
Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma. ( 28540748 )
2018
4
Management of smoldering myeloma: Recommendations of the Spanish Myeloma Group. ( 28341370 )
2017
5
Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. ( 29296837 )
2017
6
Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution. ( 27013181 )
2016
7
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM): a practical guide to management. ( 27804161 )
2016
8
Treatment of high-risk smoldering myeloma. ( 28061988 )
2016
9
High-risk smoldering myeloma: Perspective on watchful monitoring. ( 28061989 )
2016
10
Septic Arthritis & Smoldering Myeloma. ( 25862774 )
2015
11
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. ( 26490489 )
2015
12
A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients. ( 24935722 )
2014
13
Spurious platelet count due to cryoglobulins in a patient with smoldering myeloma. ( 25118751 )
2014
14
Treatment of smoldering myeloma: early or delayed? ( 24461801 )
2014
15
Classifying ultra high-risk smoldering myeloma. ( 25371175 )
2014
16
Treatment for high-risk smoldering myeloma. ( 24171527 )
2013
17
Treatment for high-risk smoldering myeloma. ( 24171530 )
2013
18
Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. ( 24145347 )
2013
19
Can NKT cells extinguish smoldering myeloma? ( 23329692 )
2013
20
Phagocytic plasma cells in a patient with smoldering myeloma. ( 23605438 )
2013
21
Treatment for high-risk smoldering myeloma. ( 24171528 )
2013
22
New approaches to smoldering myeloma. ( 23975678 )
2013
23
Treatment for high-risk smoldering myeloma. ( 24171529 )
2013
24
Treatment for high-risk smoldering myeloma. ( 24171526 )
2013
25
Smoldering myeloma presenting as progressive multifocal leukoencephalopathy: a case report. ( 22747665 )
2012
26
Increased blood viscosity and red blood cell aggregation in a patient with sickle cell anemia and smoldering myeloma. ( 22930533 )
2012
27
The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells. ( 21325290 )
2011
28
Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature. ( 20645101 )
2011
29
Monoclonal gammopathy of undetermined significance versus smoldering myeloma: is active surveillance enough? ( 21600358 )
2011
30
MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias. ( 21888257 )
2011
31
Monoclonal gammopathy of undetermined significance and smoldering myeloma: new insights into pathophysiology and epidemiology. ( 21239809 )
2010
32
Smoldering myeloma in HIV patient: a complete remission after antiretroviral therapy. ( 18221995 )
2008
33
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. ( 18669874 )
2008
34
Type 2 diabetes mellitus complicated with smoldering myeloma and non-alcoholic steatohepatitis. ( 16157983 )
2005
35
Burkholderia cenocepacia vaginal infection in patient with smoldering myeloma and chronic hepatitis C. ( 15550207 )
2004
36
Smoldering myeloma associated with zonisamide treatment. ( 11868602 )
2002
37
Scleredema and smoldering myeloma. ( 1569250 )
1992
38
Presence of clonal T cell populations in chronic B lymphocytic leukemia and smoldering myeloma. ( 2137853 )
1990

Variations for Smoldering Myeloma

Expression for Smoldering Myeloma

Search GEO for disease gene expression data for Smoldering Myeloma.

Pathways for Smoldering Myeloma

GO Terms for Smoldering Myeloma

Cellular components related to Smoldering Myeloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Golgi cisterna membrane GO:0032580 8.62 B4GALT1 FUT8

Biological processes related to Smoldering Myeloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein N-linked glycosylation GO:0006487 8.96 B4GALT1 FUT8
2 oligosaccharide biosynthetic process GO:0009312 8.62 B4GALT1 FUT8

Sources for Smoldering Myeloma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....